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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening thrombotic microangiopathy (2.9 cases/million/year) which can affect multiple organs. The clinical features of TTP are due to recurrent episodes of microangiopathic hemolytic anemia and thrombocytopenia. TTP is caused by the formation of thrombi within the microvasculature due to the inhibition of a disintegrin and metalloprotease with a thrombospondin type I domain 13 (ADAMTS13) [1] . These thrombi are composed of platelets and ultralarge von Willebrand factor (ULVWF) multimers. These multimers of VWF induce platelet aggregation and, normally, are cleaved by ADAMTS13. Acquired TTP is associated with severe VWF cleaving deficiency caused by IgG autoantibodies that inhibit ADAMTS13, which results in excessive platelet aggregation.
Exudative retinal detachment is a rare ocular complication in patients with TTP. Most of the cases are bilateral and associated with hypertension. Herein, we report a case of unilateral exudative retinal detachment without concomitant hypertension successfully treated by plasmapheresis.
Case Report
A 46-year-old North African woman presented with a sudden loss of vision. She had a medical history of TTP diagnosed 8 years ago and a severe left amblyopia since childhood (unknown etiology).
Initial ophthalmologic examination found a visual acuity limited to hand movement in the right eye and light perception in the left eye. Slit-lamp examination of the anterior segment and intraocular pressure were normal. At diagnosis, laboratory studies showed a thrombocytopenia with platelet count at 30,000/µl with a mild anemia; the hemoglobin level was 10 g/dl. The lactate dehydrogenase level was increased (2,961 IU/l). ADAMTS13 activity was undetectable (<5% of normal activity), with positive anti-ADAMTS13 antibodies. Serum creatinine and liver enzyme levels were normal. The β-hCG test was negative, and blood pressure was normal. She did not have neurologic or dermatologic symptoms.
Therefore, this exudative retinal detachment was supposed to be a complication of TTP. Plasma exchange treatment was performed (daily plasma exchange and additional treatment with corticoid starting 2 weeks after the beginning of the plasmapheresis). A few hours after the first plasmapheresis, the patient started to regain her sight, and 2 days after the first plasmapheresis, an improvement in visual acuity to 20/32 in the right eye was observed. Fundus and SD-OCT found a total disappearance of the exudative retinal detachment ( fig. 3a, b ). However, ischemia sequels were present with pigmented retinal epithelium swelling ( fig. 3c ).
Discussion
Exudative retinal detachment is a rare but reported complication of TTP. However, most patients so far had a bilateral retinal exudative detachment. The only other case of unilateral exudative retinal detachment described was due to a retinal pigment epithelium tear [2] . In our patient, the unilateral involvement can be explained by the preexisting choroidal atrophy in the left eye. Exudative retinal detachment in TTP is usually associated with hypertension. In our patient, the blood pressure was normal, and there was no other sign of hypertensive retinopathy. Only 3 other cases unrelated to hypertension have been reported [2] [3] [4] . However, for 2 of the 3 cases, other risk factors for exudative retinal detachment were present, such as a postpartum context [3] or a retinal pigment epithelium tear [2] . This suggests that hypertension probably plays an important role in the development of exudative retinal detachment in TTP, but other factors remain to be identified.
Retinal exudative detachment in TTP is supposed to be caused by a disruption of the outer retinal blood barrier and a choroidal ischemia. Microthrombi are formed by platelet aggregation, which leads to vessel occlusions that may occur in the choroidal network. Excessive platelet aggregation mediated by ULVWF multimers is caused by a failure of the proteolytic action of the metalloproteinase ADAMTS13 [5] . The plasma ADAMTS13 activity level is <5% in acute TTP [6] , as in our patient.
In case of exudative retinal detachment caused by TTP, the main treatment is plasmapheresis [7] . The efficacy of plasma exchange compared with plasma infusion was confirmed in a randomized trial [8] , and it is assumed that patients with high titers of antibodies require plasmapheresis to supply a normal protease ADAMTS13 level and remove the inhibitory antibodies (anti-ADAMTS13). This enables cleavage of ULVWF multimers and reduces excessive platelet aggregation.
Although plasmapheresis has greatly improved the mortality of TTP, it is still a potentially lethal disease [9]; therefore, it is necessary to avoid any therapeutic delay. Exudative retinal detachment can be the first manifestation of TTP, and ophthalmologists should be aware of this. 
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